In Brave New World of Follow-On Biologics, Can't We Do Better Than 1984?
This article was originally published in RPM Report
Executive Summary
Congress has moved into the final horse-trading phase of policy development regarding incentives for innovators and biosimilar product developers. The main question on Capitol Hill is what compromise can generate enough support to survive the political process. Jeffrey MOe, a Duke business school professor with experience developing incentives for drug development policy, suggest Congress should reflect before forging its political decision.